Home / Stocks / DNTH

DNTH insider trading

Dianthus Therapeutics, Inc. /DE/ — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
0
Bought · 24 mo
$0
Buys · last 90 days
0 · $0
Most recent buy

Recent insider filings

FiledInsiderTypeSharesPriceValue
2026-08-11Veness Adam M
SVP, General Counsel and Sec.
Sold16,167$110.38$1.8M
2026-08-07Garcia Marino
CEO AND PRESIDENT
Sold160,291$108.05$17.3M
2026-07-13Savitz Ryan
EVP, CFO & CBO
Sold25,683$100.83$2.6M
2026-06-18Veness Adam M
SVP, General Counsel and Sec.
Sold30,000$80.80$2.4M
2026-06-02Randhawa Simrat
EVP, Head of R&D
Sold16,943$90.72$1.5M
2026-04-01Savitz Ryan
EVP, CFO & CBO
Sold101,094$82.94$8.4M
2026-03-26Soteropoulos Paula
Director
Sold27,594$78.05$2.2M
2026-03-13Garcia Marino
CEO AND PRESIDENT
Sold121,818$81.46$9.9M
2026-03-13CARR EDWARD
CHIEF ACCOUNTING OFFICER
Sold39,317$81.33$3.2M
2026-03-13Randhawa Simrat
EVP, Head of R&D
Sold33,830$81.48$2.8M
2025-11-14Randhawa Simrat
EVP, Head of R&D
Sold151,796$37.83$5.7M

See DNTH on the chart

Every insider buy and sell for DNTH plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.